Sol-Gel Technologies Ltd. filed a Form 6-K on November 17, 2026, reporting the results of its Annual Meeting of Shareholders, at which six resolutions were approved, including a potential company name change and a three-year CEO reappointment.
Key Highlights
- Auditors reappointed: Shareholders approved the appointment of Kesselman & Kesselman, a member of PricewaterhouseCoopers International Limited, as independent auditors for 2026 and until the next annual general meeting.
- Board re-elections: Moshe Arkin, Itai Arkin, Hanna Lerman, and Sharon Kochan were each re-elected to the Board of Directors for an additional term until the 2027 annual general meeting.
- External directors renewed: Ran Gottfried and Yuval Yanai were each re-elected as external directors for a three-year term, subject to the Israeli Companies Law, 5759-1999.
- CEO appointment: Moshe Arkin, described in the filing as interim Chief Executive Officer, Executive Chairman, and controlling shareholder, was approved to serve as CEO for an additional three-year term effective January 1, 2027.
- Name change authorized: Shareholders approved a change of the company's name to "Sol-Gel Therapeutics Ltd." or "Sol-Gel Dermatology Ltd." or a similar name containing "Sol-Gel," to be implemented within 12 months of the meeting as determined by the Board.
- Share capital increase: An increase in the company's registered share capital was approved.
Sol-Gel Annual Meeting Outcomes: Six Resolutions Passed
According to the Form 6-K filed with the U.S. Securities and Exchange Commission on November 17, 2026, Sol-Gel Technologies Ltd. (NASDAQ:SLGL) reported that all six resolutions presented at its Annual Meeting of Shareholders held that day were approved. The filing was signed by Chief Financial Officer Eyal Ben-Or on behalf of the company, which is headquartered at 7 Golda Meir Street, Ness Ziona, Israel.
Among the resolutions, the filing disclosed that Moshe Arkin, who currently serves as interim Chief Executive Officer and Executive Chairman and is identified as the company's controlling shareholder, was approved to continue as CEO for three years beginning January 1, 2027. The approval is described as subject to the provisions of the Israeli Companies Law, 5759-1999. Additionally, external directors Ran Gottfried and Yuval Yanai received three-year renewals upon the expiration of their current terms, also subject to Israeli Companies Law requirements.
The name change resolution authorizes management to select among "Sol-Gel Therapeutics Ltd.," "Sol-Gel Dermatology Ltd.," or a similar name containing "Sol-Gel," contingent on approval by the Israel Registrar of Companies. The filing states the change, along with a corresponding amendment to the Articles of Association, may occur at any point within 12 months of the meeting, as determined by the Board of Directors. The Form 6-K was incorporated by reference into the company's Registration Statements on Form S-8 (Registration Nos. 333-223915, 333-270477, and 333-286820) and Form F-3 (Registration Nos. 333-286822 and 333-270478).
What Was Disclosed
Sol-Gel Technologies Ltd. reported shareholder approval of six resolutions at its November 17, 2026 Annual Meeting, covering auditor appointment, director re-elections, a CEO reappointment for three years from January 1, 2027, a potential company name change, and an increase in registered share capital.




Please wait processing your request...